Stargardt Disease (STGD) - Pipeline Insight, 2020

Publisher Name :
Date: 24-Nov-2020
No. of pages: 40
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Stargardt - Pipeline Insight, 2020," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Stargardt pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Stargardt Understanding

Stargardt: Overview

Stargardt disease is an inherited eye disease that causes vision loss in children and young adults and has a prevalence of 1 in 8000 - 10000. It is a form of macular degeneration, in which macula, a part of the retina that provides sharp, straight-ahead vision breaks down. Stargardt disease is also known as Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. The most common form of the disease is caused by a genetic mutation of the ABCA4 gene leading to the accumulation of toxic vitamin A byproducts (primarily A2E) in the retina, which results in the gradual deterioration of photoreceptors and vision.

Symptoms

The most common symptom of Stargardt disease is variable, often slow loss of central vision in both eyes. People with the disease might notice gray, black, or hazy spots in the center of their vision, or that it takes longer than usual for their eyes to adjust when moving from light to dark environments. Eyes may be more sensitive to bright light. Some people also develop color blindness later in the disease.The progression of symptoms in Stargardt disease is different for each person. People with an earlier onset of disease tend to have more rapid vision loss. Vision loss may decrease slowly at first, then worsen rapidly until it levels off. Most people with Stargardt disease will end up with 20/200 vision or worse. People with Stargardt disease may also begin to lose some of their peripheral (side) vision as they get older.

Diagnosis

A positive diagnosis of Stargardt disease by examining the retina. Lipofuscin deposits can be seen as yellowish flecks in and under the macula. The flecks are irregular in shape and usually extend outward from the macula in a ring-like pattern. Lipofuscin are fat deposits from normal cell activity and build up is more in people with Stargardt disease. The number, size, color, and appearance of these flecks are widely variable. A fluorescein angiography test may be used to diagnose Stargardt disease. Genetic testing is also available to precisely diagnose what type of macular degeneration a patient has.

Treatment

Currently, there is no proven treatments, there are three main avenues of intervention being explored, with human clinical trials of stem cell therapy, gene replacement therapy and pharmacological approaches. Gene therapy which involves repairing or replacing the defective ABCA4 gene also holds promise for treating Stargardt disease. A number of services and devices can help people with Stargardt disease carry out daily activities and maintain their independence. Wearing sunglasses may help with the bright light sensitivity of Stargardt disease and also prevent further retina damage from the sun's harmful ultraviolet (UV) rays. Stargardt disease pateints should not smoke cigarettes or be around cigarette smoke. Also, some studies suggest that taking a lot of vitamin A could may make the disease worse.

Stargardt Emerging Drugs Chapters

This segment of the Stargardt report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Stargardt Emerging Drugs

- Emixustat: Kubota Vision

Emixustat hydrochloride (emixustat, formerly ACU-4429) is an experimental drug that is a Retinoid isomerohydrolase inhibitor. It is an orally administered small molecule that inhibits the visual cycle isomerohydrolase, RPE65. The FDA (U.S. Food and Drug Administration) and European Medicines Agency (EMA) granted orphan drug designation to emixustat for the treatment of Stargardt disease.

- ALK-001: Alkeus Pharmaceuticals

ALK-001 is once-a-day oral drug candidate currently in Phase 2 for the treatment of Stargardt disease. Due to a genetic defect in Stargardt, toxic vitamin A aggregates called "dimers" are known to rapidly form and cause the degeneration of the retina. ALK-001 is form of vitamin A that has been chemically-modified to prevent vitamin A aggregation into dimers.

Further product details are provided in the report……..

Stargardt: Therapeutic Assessment

This segment of the report provides insights about the different Stargardt drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Stargardt

There are approx. 8+ key companies which are developing the therapies for Stargardt. The companies which have their Stargardt drug candidates in the most advanced stage, i.e. phase III include, Kubota Vision.

- Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Stargardt pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravitreal

- Subretinal

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Stargardt: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Stargardt therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stargardt drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Stargardt R&D. The therapies under development are focused on novel approaches to treat/improve Stargardt.

- On October 28, 2020, reVision Therapeutics, Inc developing candidate REV-0100 received Orphan-Drug and a Rare Pediatric Disease Drug designation for the treatment of Stargardt disease.

Stargardt Report Insights

- Stargardt Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Stargardt Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Stargardt drugs?

- How many Stargardt drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Stargardt?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Stargardt therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Stargardt and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Kubota Vision Inc.

- Alkeus Pharmaceuticals

- Stargazer Pharmaceuticals, Inc.

- IVERIC bio, Inc.

- Astellas Pharma, Inc.

- Cardax Pharmaceuticals

- Beam Therapeutics

- Belite Bio

Key Products

- Emixustat

- ALK-001

- Zeaxanthin

- STG 001

- Avacincaptad pegol

- ASP7317

- LBS-008

Stargardt Disease (STGD) - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Stargardt: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Stargardt - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Stargardt companies' collaborations, Licensing, Acquisition -Deal Value Trends
Stargardt Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Emixustat: Kubota Vision
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
ALK-001: Alkeus Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
LBS-008: Belite Bio
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Zeaxanthin - Cardax Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Stargardt Key Companies
Stargardt Key Products
Stargardt- Unmet Needs
Stargardt- Market Drivers and Barriers
Stargardt- Future Perspectives and Conclusion
Stargardt Analyst Views
Stargardt Key Companies
Appendix


List of Tables

Table 1 Total Products for Stargardt
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for Stargardt
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 99
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and Neural Disease Segment by Application - Hospi......
  • Global rhEPO Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 97
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and neural disease Segment by Application - Hospi......
  • Global Rhematoid Arthritis Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 94
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Pharmaceuticals - Biopharmaceuticals Segment by Application - Prescription - OTC......
  • Global Chronic Obstructive Pulmonary Disease Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 118
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Inhalers - Nebulizers Segment by Application - Emphysema - Chronic Bronchitis ......
  • Global Chronic Lymphocytic Leukemia Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 121
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Acutemyeloid (ormyelogenous)leukemia (AML) - Chronicmyeloid (ormyelogenous)leukemia (CML) - Acutelymphocyti......
  • Global Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 5-HT3 Inhibitors - NK1 Inhibitors - Other Segment by Application - Highly Emetogenic ......
  • Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Aloxi (Palonosetron) - Kytril Generic (Granisetron) - Emend (Aprepitant) - Akynzeo (Netupitant-Palon......
  • Global ß-blockers Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 122
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nonselective Agents - Selective Agents Segment by Application - Abnormal Heart Rhythms......
  • Global a-adrenoreceptor Antagonists Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 116
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Non-selective Antagonists - Selective Antagonists Segment by Application - Hypertension......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs